Exploring Barriers and Facilitators to Participation of Male-to-female Transgender Persons in Preventive HIV Vaccine Clinical Trials

Overview

Journal Prev Sci

Specialty Science

Date 2013 Mar 1

PMID 23446435

Citations 39

Authors

Michele Peake Andrasik

Ro Yoon

Jessica Mooney

Gail Broder

Marcus Bolton

Teress Votto

Annet Davis-Vogel

Affiliations

Soon will be listed here.

Abstract

Observed seroincidence and prevalence rates in male-to-female (MTF) transgender individuals highlight the need for effective targeted HIV prevention strategies for this community. In order to develop an effective vaccine that can be used by transgender women, researchers must understand and address existing structural issues that present barriers to this group's participation in HIV vaccine clinical trials. Overcoming barriers to participation is important for ensuring HIV vaccine acceptability and efficacy for the MTF transgender community. To explore barriers and facilitators to MTF transgender participation in preventive HIV vaccine clinical trials, the HIV Vaccine Trials Network conducted focus groups among transgender women in four urban areas (Atlanta, Boston, Philadelphia, and San Francisco). Barriers and facilitators to engagement of transgender women in preventive HIV vaccine clinical trials led to the following recommendations: (a) transgender cultural competency training, (b) creating trans-friendly environments, (c) true partnerships with local trans-friendly organizations and health care providers, (d) protocols that focus on transgender specific issues, and (e) data collection and tracking of transgender individuals. These results have implications for the conduct of HIV vaccine trials, as well as engagement of transgender women in research programs in general.

Citing Articles

Developing Guidelines for Conducting Stigma Research With Transgender and Nonbinary Individuals: Protocol for Creation of a Trauma-Informed Approach to Research.

Klein A, Golub S, Berke D, Castle E JMIR Res Protoc. 2025; 14:e66800.

PMID: 39761548 PMC: 11747536. DOI: 10.2196/66800.

Improving Recruitment and Retention of Transgender Women in HIV Prevention Trials: Strategies to Make Trial Participation More Congruent with the Needs of Transgender Women.

Das D, Lopez-Rios J, McKenna S, Porter J, Dolezal C, Giffenig P AIDS Res Hum Retroviruses. 2024; 40(12):680-689.

PMID: 39003524 PMC: 11693950. DOI: 10.1089/AID.2023.0063.

Influences on clinical trial participation: Enhancing recruitment through a gender lens - A scoping review.

Hawke L, Nelson E, OBrien P, Crossley K, Choong P, Bunzli S Contemp Clin Trials Commun. 2024; 38:101283.

PMID: 38456181 PMC: 10918492. DOI: 10.1016/j.conctc.2024.101283.

Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.

Meskell P, Biesty L, Dowling M, Roche K, Meehan E, Glenton C Cochrane Database Syst Rev. 2023; 9:MR000065.

PMID: 37655964 PMC: 10472890. DOI: 10.1002/14651858.MR000065.pub2.

Engaging transgender women in HIV research in South Africa.

van der Merwe L, Cloete A, Savva H, Skinner D, November G, Fisher Z BMC Public Health. 2023; 23(1):990.

PMID: 37248495 PMC: 10226201. DOI: 10.1186/s12889-023-15977-1.

References

Voytek C, Jones K, Metzger D . Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine. 2011; 29(36):6130-5. PMC: 3164286. DOI: 10.1016/j.vaccine.2011.06.064. View

Newman P, Duan N, Roberts K, Seiden D, Rudy E, Swendeman D . HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006; 41(2):210-7. DOI: 10.1097/01.qai.0000179454.93443.60. View

Sanchez N, Sanchez J, Danoff A . Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health. 2009; 99(4):713-9. PMC: 2661470. DOI: 10.2105/AJPH.2007.132035. View

Sobieszczyk M, Xu G, Goodman K, Lucy D, Koblin B . Engaging members of African American and Latino communities in preventive HIV vaccine trials. J Acquir Immune Defic Syndr. 2009; 51(2):194-201. PMC: 4465439. DOI: 10.1097/qai.0b013e3181990605. View

Young R, Meyer I . The trouble with "MSM" and "WSW": erasure of the sexual-minority person in public health discourse. Am J Public Health. 2005; 95(7):1144-9. PMC: 1449332. DOI: 10.2105/AJPH.2004.046714. View

Clements-Nolle K, Marx R, Guzman R, Katz M . HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention. Am J Public Health. 2001; 91(6):915-21. PMC: 1446468. DOI: 10.2105/ajph.91.6.915. View

Elifson K, Boles J, POSEY E, Sweat M, Darrow W, Elsea W . Male transvestite prostitutes and HIV risk. Am J Public Health. 1993; 83(2):260-2. PMC: 1694585. DOI: 10.2105/ajph.83.2.260. View

Snelgrove J, Jasudavisius A, Rowe B, Head E, Bauer G . "Completely out-at-sea" with "two-gender medicine": a qualitative analysis of physician-side barriers to providing healthcare for transgender patients. BMC Health Serv Res. 2012; 12:110. PMC: 3464167. DOI: 10.1186/1472-6963-12-110. View

Kenagy G . HIV among transgendered people. AIDS Care. 2002; 14(1):127-34. DOI: 10.1080/09540120220098008. View

10.

Edwards J, Fisher D, Reynolds G . Male-to-female transgender and transsexual clients of HIV service programs in Los Angeles County, California. Am J Public Health. 2007; 97(6):1030-3. PMC: 1874200. DOI: 10.2105/AJPH.2006.097717. View

11.

Nemoto T, Operario D, Keatley J, Nguyen H, Sugano E . Promoting health for transgender women: Transgender Resources and Neighborhood Space (TRANS) program in San Francisco. Am J Public Health. 2005; 95(3):382-4. PMC: 1449187. DOI: 10.2105/AJPH.2004.040501. View

12.

Bockting W, Rosser B, Scheltema K . Transgender HIV prevention: implementation and evaluation of a workshop. Health Educ Res. 1999; 14(2):177-83. DOI: 10.1093/her/14.2.177. View

13.

Kenagy G . Transgender health: findings from two needs assessment studies in Philadelphia. Health Soc Work. 2005; 30(1):19-26. DOI: 10.1093/hsw/30.1.19. View

14.

Newman P, Logie C . HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010; 24(11):1749-56. DOI: 10.1097/qad.0b013e32833adbe8. View

15.

Kellogg T, Clements-Nolle K, Dilley J, Katz M, McFarland W . Incidence of human immunodeficiency virus among male-to-female transgendered persons in San Francisco. J Acquir Immune Defic Syndr. 2001; 28(4):380-4. DOI: 10.1097/00126334-200112010-00012. View

16.

Moutsiakis D, Chin P . Why blacks do not take part in HIV vaccine trials. J Natl Med Assoc. 2007; 99(3):254-7. PMC: 2569631. View

17.

Boyce S, Barrington C, Bolanos H, Arandi C, Paz-Bailey G . Facilitating access to sexual health services for men who have sex with men and male-to-female transgender persons in Guatemala City. Cult Health Sex. 2011; 14(3):313-27. DOI: 10.1080/13691058.2011.639393. View

18.

Nemoto T, Luke D, MAMO L, Ching A, Patria J . HIV risk behaviours among male-to-female transgenders in comparison with homosexual or bisexual males and heterosexual females. AIDS Care. 1999; 11(3):297-312. DOI: 10.1080/09540129947938. View

19.

Nemoto T, Sausa L, Operario D, Keatley J . Need for HIV/AIDS education and intervention for MTF transgenders: responding to the challenge. J Homosex. 2006; 51(1):183-202. DOI: 10.1300/J082v51n01_09. View

20.

Bockting W, Robinson B, Rosser B . Transgender HIV prevention: a qualitative needs assessment. AIDS Care. 1998; 10(4):505-25. DOI: 10.1080/09540129850124028. View